Evidence-based treatment of the antiphospholipid syndrome: I. Pregnancy failure

Thrombosis Research

Volumn 114, Issue 2, 2004, Pages 75-81

  Wisløff, Finn ^c   Crowther, Mark ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b MCMASTER UNIVERSITY   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; HEMOGLOBIN; HEPARIN; IMMUNOGLOBULIN; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PREDNISONE; TISSUE PLASMINOGEN ACTIVATOR;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; CONFIDENCE INTERVAL; EMBRYO DEVELOPMENT; EVIDENCE BASED MEDICINE; FETUS DEATH; FETUS WASTAGE; GROWTH RETARDATION; HEMOSTASIS; HUMAN; PLASMAPHERESIS; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DISORDER; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ABORTION, HABITUAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; FEMALE; FETAL DEATH; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PHYSICIAN'S PRACTICE PATTERNS; PREDNISONE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; TREATMENT OUTCOME;

EID: 4043139308     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.05.006     Document Type: Review

References (53)

1. Asherson R.A., Cervera R., Piette J.-C., Shoenfeld Y. The antiphospholipid syndrome II. 2002;Elsevier, Amsterdam. [Ref Type: Generic]
2. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. [see comments, Review, 22 refs] Arthritis Rheum. 42(7):1999;1309-1311
3. Lockshin M.D., Sammaritano L.R., Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. [see comments] Arthritis Rheum. 43(2):20000;440-443
4. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 46(4):2002;1019-1027
5. Love P.E., Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. [Review, 178 refs] Ann. Intern. Med. 112(9):1990;682-698
6. Alarcon-Segovia D., Perez-Vazquez M.E., Villa A.R., Drenkard C., Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin. Arthritis Rheum. 21(5):1992;275-286
7. Wahl D.G., Guillemin F., de Maistre E., Perret C., Lecompte T., Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - a meta-analysis. Lupus. 6(5):1997;467-473
8. Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104(4):1998;332-338
9. Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. [see comments, erratum appears in N Engl J Med 1999 Jul 22;341(4):298.] N. Engl. J. Med. 340(12):1999;901-907
10. Vaarala O., Manttari M., Manninen V., Tenkanen L., Puurunen M., Aho K., et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 91(1):1995;23-27
11. Brey R.L., Abbott R.D., Curb J.D., Sharp D.S., Ross G.W., Stallworth C.L., et al. beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. [see comments] Stroke. 32(8):2001;1701-1706
12. Wisloff F., Jacobsen E.M., Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. [Review, 102 refs] Thromb. Res. 108(5-6):2002;263-271
13. Nilsson I.M., Astedt B., Hedner U., Berezin D. Intrauterine death and circulating anticoagulant ("antithromboplastin"). Acta Med. Scand. 197(3):1975;153-159
14. Lockshin M.D., Druzin M.L., Goei S., Qamar T., Magid M.S., Jovanovic L., et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N. Engl. J. Med. 313(3):1985;152-156
15. Ginsberg J.S., Brill-Edwards P., Johnston M., Denburg J.A., Andrew M., Burrows R.F., et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. [comment] Blood. 80(4):1992;975-980
16. Branch D.W., Scott J.R., Kochenour N.K., Hershgold E. Obstetric complications associated with the lupus anticoagulant. N. Engl. J. Med. 313(21):1985;1322-1326
17. Lockwood C.J., Romero R., Feinberg R.F., Clyne L.P., Coster B., Hobbins J.C. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. [comment] Am. J. Obstet. Gynecol. 161(2):1989;369-373
18. Gris J.C., Perneger T.V., Quere I., Mercier E., Fabbro-Peray P., Lavigne-Lissalde G., et al. Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood. 102(10):2003;3504-3513
19. Franklin R.D., Kutteh W.H. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. [see comment] Hum. Reprod. 17(11):2002;2981-2985
20. Parke A.L., Wilson D., Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum. 34(10):1991;1231-1235
21. Parazzini F., Acaia B., Faden D., Lovotti M., Marelli G., Cortelazzo S. Antiphospholipid antibodies and recurrent abortion. Obstet. Gynecol. 77(6):1991;854-858
22. MacLean M.A., Cumming G.P., McCall F., Walker I.D., Walker J.J. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br. J. Obst. Gynaecol. 101(2):1994;103-106
23. Rai R.S., Regan L., Clifford K., Pickering W., Dave M., Mackie I., et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum. Reprod. 10(8):1995;2001-2005
24. Infante-Rivard C., David M., Gauthier R., Rivard G.E. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. [see comment] N. Engl. J. Med. 325(15):1991;1063-1066
25. Out H.J., Kooijman C.D., Bruinse H.W., Derksen R.H. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur. J. Obstet. Gynecol. Reprod. Biol. 41(3):1991;179-186
26. Rand J.H., Wu X.X., Andree H.A., Lockwood C.J., Guller S., Scher J., et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. [comment, erratum appears in N Engl J Med 1997 Oct 30;337(18):1327] N. Engl. J. Med. 337(3):1997;154-160
27. Gharavi A.E., Pierangeli S.S., Levy R.A., Harris E.N. Mechanisms of pregnancy loss in antiphospholipid syndrome. [Review, 56 refs] Clin. Obst. Gynecol. 44(1):2001;11-19
28. Rand J.H. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome. [Review, 42 refs] J. Autoimmun. 15(2):2000;107-111
29. Bevers E.M., Janssen M.P., Willems G.M., Zwaal F.A. No evidence for enhanced thrombin formation through displacement of annexin V by antiphospholipid antibodies. [comment] Thromb. Haemost. 83(5):2000;792-794
30. Sthoeger Z.M., Mozes E., Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc. Natl. Acad. Sci. U. S. A. 90(14):1993;6464-6467
31. Chamley L.W., Duncalf A.M., Mitchell M.D., Johnson P.M. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet. 352(9133):1998;1037-1038
32. Altman D.G., Machin D., Bryant T.N., Gardner M. Statistics with confidence. Second edition:2000;BMJ Books, Bristol. Ref Type: Generic
33. Blank M., Cohen J., Toder V., Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc. Natl. Acad. Sci. U. S. A. 88(8):1991;3069-3073
34. Lubbe W.F., Butler W.S., Palmer S.J., Liggins G.C. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet. 1(8338):1983;1361-1363
35. Cowchock F.S., Reece E.A., Balaban D., Branch D.W., Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am. J. Obstet. Gynecol. 166(5):1992;1318-1323
36. Silver R.K., MacGregor S.N., Sholl J.S., Hobart J.M., Neerhof M.G., Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am. J. Obstet. Gynecol. 169(6):1993;1411-1417
37. Frampton G., Cameron J.S., Thom M., Jones S., Raftery M. Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. Lancet. 2(8566):1987;1023-1024
38. Branch D.W., Peaceman A.M., Druzin M., Silver R.K., El Sayed Y., Silver R.M., et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am. J. Obstet. Gynecol. 182(1:Pt 1):2000;t-7
39. Triolo G., Ferrante A., Ciccia F., Accardo-Palumbo A., Perino A., et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum. 48(3):2003;728-731
40. Pattison N.S., Chamley L.W., Birdsall M., Zanderigo A.M., Liddell H.S., McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial [see comments]. Am. J. Obstet. Gynecol. 183(4):2000;1008-1012
41. Rosove M.H., Tabsh K., Wasserstrum N., Howard P., Hahn B.H., Kalunian K.C. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies [comment]. Obstet. Gynecol. 75(4):1990;630-634
42. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am. J. Obstet. Gynecol. 174(5):1996;1584-1589
43. Rai R., Cohen H., Dave M., Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) [see comments]. BMJ. 314(7076):1997;253-257
44. Empson M., Lassere M., Craig J.C., Scott J.R. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet. Gynecol. 99(1):2002;135-144. [Review] [44 refs]
45. Cowchock S., Reece E.A. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am. J. Obstet. Gynecol. 176(5):1997;1099-1100
46. Tulppala M., Marttunen M., Soderstrom-Anttila V., Foudila T., Ailus K., Palosuo T., et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum. Reprod. 12(7):1997;1567-1572
47. Laskin C.A., Bombardier C., Hannah M.E., Mandel F.P., Ritchie J.W., Farewell V., et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss [comment]. N. Engl. J. Med. 337(3):1997;148-153
48. Rote N.S. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials [comment]. Obstet. Gynecol. 100(1):2002;173-174
49. Sherer Y., Levy Y., Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology. 39(4):2000;421-426. [Review] [59 refs]
50. Pettila V., Leinonen P., Markkola A., Hiilesmaa V., Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin [see comment]. Thromb. Haemost. 87(2):2002;182-186
51. Farquharson R.G., Quenby S., Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet. Gynecol. 100(3):2002;408-413
52. Hasegawa I., Yamanoto Y., Suzuki M., Murakawa H., Kurabayashi T., Takakuwa K., et al. Prednisolone plus low-dose aspirin improves the implantation rate in women with autoimmune conditions who are undergoing in vitro fertilization. Fertil. Steril. 70(6):1998;1044-1048
53. Sher G., Zouves C., Feinman M., Maassarani G., Matzner W., Chong P., et al. A rational basis for the use of combined heparin/aspirin and IVIG immunotherapy in the treatment of recurrent IVF failure associated with antiphospholipid antibodies. Am. J. Reprod. Immunol. 39(6):1998;391-394